On November 4, 2026, a clinical trial involving bivalirudin was updated to active, not recruiting status. The study, registered as NCT03537586 and titled "A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction," is listed with a phase designation of NA, indicating it is not a standard phased interventional trial.
The trial is a single center, diagnostic, cross-sectional study, according to its registration record. Its current status means the study is ongoing but is no longer enrolling new participants. No results have been posted in connection with this status update.
Bivalirudin remains an approved compound, and this trial update reflects only a change in recruitment status, not new efficacy or safety findings. The registration record does not include outcome data, and none should be assumed from this status change alone.
Readers interested in the design or purpose of this diagnostic study can consult the official registration page for full protocol details, inclusion criteria, and sponsor information. Additional updates to recruitment status, completion, or results may follow as the study progresses through its stated single center cross-sectional design.
For more background on this compound, see the linked compound overview.